Management said patient growth continued through the fourth quarter. The company reported ending the quarter with more than 36,250 patients on Rezdiffra, up from more than 29,500 at the end of the third quarter. Sibold noted the patient figure reflects the net of new starts and discontinuations.Sibold attributed the commercial performance to building the market “from scratch,” including prescriber education, establishing care pathways, expanding prescriber breadth and depth, and contracting for access. He a ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker10Good morning, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' fourth quarter and full year 2025 earnings conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. As a reminder, today's conference call is being recorded. I would now like to introduce Ms. Tina Ventura, Chief Investor Relations ...

4Q25 Financial Results Feb. 19, 2026 NASDAQ: MDGL © 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumpt ...

Core Viewpoint - Madrigal Pharmaceuticals is positioned as a leading company in the metabolic and liver disease sector, with significant accomplishments over the past two years and a strong outlook for the future [2][3]. Company Overview - Madrigal Pharmaceuticals has been recognized as one of the most consequential companies in the metabolic and liver disease space in recent years [2]. - The company is led by CEO Bill Sibold, CMO Dr. David Soergel, and CFO Mardi Dier, who are actively engaging with stakeholders to provide updates on the company's progress [2]. Strategic Focus - The company's primary mission is to lead the fight against MASH (Metabolic Associated Steatotic Hepatitis), which reflects its commitment to addressing critical health challenges in this area [4]. - Madrigal emphasizes the importance of leadership and innovation in its approach to tackling MASH, aiming to differentiate itself within the industry [4].